Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New prostate cancer marker helps identify men whose cancer is likely to spread

05.10.2006
Prostate cancer researchers at Sydney's Garvan Institute, supported by the Cancer Institute NSW, have found a new marker for identifying aggressive prostate cancers.

Many men with prostate cancer have their prostate glands removed, but only a proportion of these men will later develop life-threatening metastatic disease – where the cancer spreads to other parts of the body such as the bones. This new marker can identify which men are at the highest risk of metastatic disease at the time of their initial surgery leading to tailored treatment for individual prostate cancer sufferers, something that is not currently possible.

A/Prof Sue Henshall, who leads the prostate cancer research group, says: "We have discovered that men who have low levels of a marker called AZGP1 in the prostate at the time of surgery, have a greatly increased risk of developing metastatic cancer. This means two things: that these men could benefit from more aggressive treatment such as radiotherapy or chemotherapy around the time of surgery when they still have potentially curable cancer; and that patients with a low risk of developing metastatic disease will have the option of deferring treatments that have a negative impact on quality of life."

The next step is to explore the relationship between low levels of AZGP1 and the development of metastatic cancer in other groups of men with prostate cancer (i.e. other prostate cancer tissue banks). "It is important to begin testing for this marker now because in the next decade, when the outcomes for some of these new patients is known, we will be able to see just how predictive our marker is in the clinic", said Garvan's Cancer Program Director Professor Rob Sutherland.

"A/Prof Sue Henshall's research has put Australia at the forefront of world research in developing efficient prognostic tools in prostate cancer," said Prof Jim Bishop, Chief Cancer Officer NSW and CEO of Cancer Institute NSW, which funded the research as part of a $3.7 million Program Grant for Excellence in Translational Research.

Branwen Morgan | EurekAlert!
Further information:
http://www.garvan.org.au

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Staying in Shape

16.08.2018 | Life Sciences

Diving robots find Antarctic seas exhale surprising amounts of carbon dioxide in winter

16.08.2018 | Earth Sciences

Protein droplets keep neurons at the ready and immune system in balance

16.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>